Bisphenol-A Impairs Insulin Action and Up-Regulates Inflammatory Pathways in Human Subcutaneous Adipocytes and 3T3-L1 Cells

Rossella Valentino¹, Vittoria D’Esposito², Federica Passaretti²,³, Antonietta Liotti²,³, Serena Cabaro², Michele Longo², Giuseppe Perruolo¹, Francesco Oriente², Francesco Beguinot¹,², Pietro Formisano¹,²*

¹Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS-CNR), Naples, Italy, ²Dipartimento di Scienze Mediche Traslazionali, Università degli Studi di Napoli "Federico II", Naples, Italy, ³Dipartimento di Scienze Farmaceutiche, Università degli Studi di Salerno, Salerno, Italy

Abstract

Current evidence indicates that chemical pollutants may interfere with the homeostatic control of nutrient metabolism, thereby contributing to the increased prevalence of metabolic disorders. Bisphenol-A (BPA) is a lipophilic compound contained in plastic which is considered a candidate for impairing energy and glucose metabolism. We have investigated the impact of low doses of BPA on adipocyte metabolic functions. Human adipocytes derived from subcutaneous adipose tissue and differentiated 3T3-L1 cells were incubated with BPA, in order to evaluate the effect on glucose utilization, insulin sensitivity and cytokine secretion. Treatment with 1nM BPA significantly inhibited insulin-stimulated glucose utilization, without grossly interfering with adipocyte differentiation. Accordingly, mRNA levels of the adipogenic markers PPARG and GLUT4 were unchanged upon BPA exposure. BPA treatment also impaired insulin-activated receptor phosphorylation and signaling. Moreover, adipocyte incubation with BPA was accompanied by increased release of IL-6 and IFN-γ, as assessed by multiplex ELISA assays, and by activation of JNK, STAT3 and NFkB pathways. Treatment of the cells with the JNK inhibitor SP600125 almost fully reverted BPA effect on insulin signaling and glucose utilization. In conclusion, low doses of BPA interfere with inflammatory/insulin signaling pathways, leading to impairment of adipose cell function.

Introduction

Overweight, obesity and insulin resistance epidemics are significant human health problems in adults, but also in children and adolescents [1,2]. They are associated with increased risk of diseases related to metabolic dysfunctions, including metabolic syndrome (MS), type 2 diabetes mellitus (T2D), coronary heart disease (CHD), and some forms of cancer [3–6]. Chronic inflammation often accompanies obesity and related disorders, suggesting that inflammatory factors might be a crucial culprit connecting adipose tissue dysfunction with insulin resistance and diabetes as well as with cardiovascular disease and cancer [5–9].

Environmental signals, including chemical pollutants, are now considered contributing factors for insulin resistance [10–13]. Most of chemical pollutants potentially accumulate into adipose tissue [14], and could be responsible, in addition to the well-known dietary and lifestyle habits, for overweight and obesity epidemic, driving the parallel T2D epidemic [13,15–17].

The “environmental obesogen hypothesis” has been associated to the adipose tissue inflammatory phenotype, with hypersecretion of pro-inflammatory and decrease of anti-inflammatory cytokines, and considered as a major contributing factor for the decreased insulin sensitivity [7–10]. Indeed, the exponential rise of obesity-related pathologies worldwide is associated with the marked increase of toxic chemicals in the environment. In the modern world, in fact, the environment has been largely affected by an ever increasing number of synthetic chemical lipophilic pollutants, such as pesticides, organophosphates, polychlorinated bisphenyls, phthalates, solvents etc., that permeate the diet, the air and the ground [15,16,18–20]. An even larger impact could be exerted by those which are resistant to biological and chemical degradation, also termed Persistent Organic Pollutants (POPs), most of them also classified as endocrine disruptors [15–20].

Bisphenol-A (BPA) represents a potential obesogen compound and has been studied for its estrogen mimetic activity and endocrine disruption [21–24]. BPA is found in products containing polycarbonate plastics and in resins, as lining for metal cans and as an additive in other widely used plastics [25–27]. It is a lipophilic compound detectable at nanomolar levels not only in food and tap water, in rivers, lakes and sea, but also in human blood samples and urine worldwide, as well as in the placenta, amniotic fluid of pregnant women and in human milk [28,29]. In animal models, BPA has been shown to disrupt the major weight controlling hormones, such as thyroid hormones, estrogens, testosterone, corticosteroids, growth hormone and leptin, and to
alter adipogenesis, beta-cell and endocrine pancreas function [24,30–32]. The relationship between BPA, inflammation and insulin sensitivity in adipose tissue is still not well understood.

Thus, we have investigated whether BPA, at nanomolar doses, consistent with those found in the human bloodstream and/or in environment, could interfere with adipose tissue function. We found that, in cultured adipose cells derived from human subcutaneous tissue and in 3T3-L1 adipocytes, BPA exposure impaired insulin sensitivity and glucose utilization and enhanced the release of pro-inflammatory compounds, even in the absence of major derangement of adipocyte differentiation.

**Materials and Methods**

**Materials**

Media, sera, and antibiotics for cell culture were from Lonza (Lonza Group Ltd, Basel, Switzerland). Antibodies against phospho-Ser473PKB/Akt1, ERK, phospho-Thr183/Tyr185c-Jun N-terminal kinase (JNK), STAT3, NFkB, Laminin A/C and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Phospho-Thr202/Tyr204ERK, Phospho-IGF1-Receptor beta Tyr1131/Insulin Receptor beta Tyr 1146, Insulin Receptor beta and Phospho-Tyr705 STAT3 antibodies were obtained from Cell Signaling Technology (Danvers, MA). PKB/Akt antibody was

| Table 1. Primer sequences used in Real-time RT-PCR analysis. |
| --- |
| PPAR-γ Forward | 5’- TGG TGC CTTGCTCATGC -3’ |
| PPAR-γ Reverse | 5’- CTG TGG TAA AGG GCT TGA TGTC -3’ |
| GLUT4 Forward | 5’- CAG AAG GTG ATT GAA CAG AG-3’ |
| GLUT4 Reverse | 5’- AAT GAT GCC AAT GAG AAA GG-3’ |
| GLUT1 Forward | 5’- GGG AAT GTC CTC ATC TG TGA G-3’ |
| GLUT1 Reverse | 5’- TGA GGC TCT GTG TGG TTC TG -3’ |
| LEPTIN Forward | 5’-ACTCCACAATGCTTGACT-3’ |
| LEPTIN Reverse | 5’-CCTACCTCACCTTCCTG -3’ |
| β-actin Forward | 5’- GCC CCT AGG CAC CAG GGT GTG -3’ |
| β-actin Reverse | 5’- TCG GTG AGC AGC ACA GGG TG -3’ |

Figure 1. Effect of BPA on adipocyte glucose utilization. Human adipocytes (a) and 3T3-L1 adipocytes (b) were incubated in serum free-media with 1 nM or 100 nM BPA and 100 nM insulin for 24 and 48h as indicated. Next, supernatants were collected and glucose consumption was determined as described in Materials and Methods. Bars represent the mean ± SD of three independent experiments. Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. *p values of less than 0.05 were considered statistically significant. Asterisks indicate statistically significant differences (* p<0.05). Error bars indicate mean ± S.D.

doi:10.1371/journal.pone.0082099.t001
doi:10.1371/journal.pone.0082099.g001
from Millipore (Billerica, MA). BPA in ethanol was a generous gift of Prof. C. Crescenzi (Department of Pharmaceutical Science, University of Salerno, Italy). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) reagents were from Bio-Rad (Hercules, CA). All the other chemicals were from Sigma-Aldrich (St. Louis, MO).

Cell cultures

Human adipose tissue samples were obtained by abdominal biopsy in the periumbilical region under local anesthesia (2% lidocaine) from patients undergoing elective abdominal surgery for gall bladder disease. The study was approved by the Ethic Committee of the University of Napoli “Federico II”. The written informed consent with respect to taking the samples and making the cell lines was obtained before the biopatical procedure. The study protocol was conducted in accordance to the principles of the Declaration of Helsinki as revised in 2000. Adipose tissue was digested with collagenase and Adipose-derived Stromal Vascular Fraction cells (SVF) were isolated and differentiated as previously reported [6].

Table-1-caption

3T3-L1 mouse embryonic fibroblasts (ATCC-CL-173, American Type Culture Collection, Manassas, VA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mmol/l glutamine, 100 IU/ml penicillin, 100 IU/ml streptomycin. Cultures were maintained in humidified atmosphere of 95% air and 5% CO₂ at 37 C. 3T3-L1 differentiation has been achieved as previously described [6].

Conditioned media were obtained by incubating the cells for 8 h with serum-free DMEM 0.25% BSA after two washes with PBS. After the incubation, medium was collected and centrifuged at 14000g to remove cellular debris and analyzed for cytokine content, as described below.

Glucose Utilization

Table-1-caption

For glucose utilization studies, the method previously described [33] was modified for human adipocytes and 3T3-L1 adipocytes. Adipocytes were incubated in serum-free media containing 0.25% BSA in the absence or presence of 1 nM–100 nM BPA and 100 nM insulin for 24–48h. Glucose concentration was measured in the medium before and after the incubation.

Table-1-caption

The difference in glucose concentration was considered to be utilized by the cells. Quantitative analysis of glucose concentration was performed with a ABX Pentra 400 clinical chemistry analyzer using the reagent ABX Pentra Glucose CP (ABX-Horiba, Montpellier, France) according to the manufacturer’s instructions.

Immunoblot procedure

Table-1-caption

Total cell lysates and, where indicated, cytosolic and nuclear fractions were obtained, separated by SDS-PAGE and immunoblotted with specific antibodies as previously described [34–35].

Cytokine Assay

Human and 3T3-L1 adipocytes conditioned media were screened for the concentration of IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-γ, KC/IL-8, MCP-1, MIP-1α, MIP-1β, RANTES and TNF-α using the Bioplex multiplex Mouse and Human Cytokine kits (Bio-Rad) according to the manufacturer’s protocol as previously described [6].

Real-time RT-PCR analysis

Table-1-caption

Total RNA was isolated from 3T3-L1 adipocytes by using the RNase Kit (Qiagen Sciences) according to the manufacturer’s instruction. For real-time RT-PCR analysis, 1 μg cell RNA was reverse transcribed using Super Script II Reverse Transcriptase (Invitrogen). PCR were analyzed using SYBR

Figure 2. Effect of BPA on adipocyte gene expression. 3T3-L1 cells have been differentiated in mature adipocytes in presence of BPA 1 nM. Next, mRNA levels of PPARγ (a), GLUT4 (b) and GLUT1 (c) during adipogenic differentiation were determined by real-time RT-PCR analysis. Bars represent the mean ± SD of four independent experiments and show the mRNA levels in these cells relative to those in 3T3-L1 cells in absence of BPA at day 2 of differentiation. Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically significant. Asterisks indicate statistically significant differences (*p<0.05). Error bars indicate mean ± S.D.

doi:10.1371/journal.pone.0082099.g002
Green mix (Invitrogen). Reactions were performed using Platinum SYBR Green Quantitative PCR Super-UDG using an iCycler IQmulticolor Real-Time PCR Detection System (Bio-Rad). All reactions were performed in triplicate and β-actin was used as an internal standard. Primer sequences used were described in Table 1.

Figure 3. Effect of BPA on insulin transduction pathways. Human (a) and 3T3-L1 adipocytes (c) were incubated with 1 nM BPA for 24 and 48h as indicated and exposed to 100 nM insulin for 10 min and then solubilized as described in Materials and Methods. Cell lysates (50 μg protein/sample) were blotted with phospho- Tyr1146 Insulin Receptor (pIR), phospho- Ser473Akt/PKB and phospho-Thr202/Tyr204Extracellular signal-Regulated Kinases (pERK) antibodies and then rebotted with anti-IR, Akt/PKB and ERK antibodies. To ensure the equal protein transfer, membranes were blotted with actin antibodies. The filters were revealed by ECL and autoradiography. The autoradiographs shown are representative of four independent experiments. b-d) Filters obtained in a and c have been analyzed by laser densitometry as described under Materials and Methods. Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically significant. Asterisks indicate statistically significant differences (*p < 0.05). Error bars indicate mean ± S.D.

doi:10.1371/journal.pone.0082099.g003
Figure 4. Effect of BPA on leptin mRNA levels. 3T3-L1 adipocytes were incubated with 1 nM BPA for 24h and leptin mRNA levels were determined by real-time RT-PCR analysis. Bars represent the mean ± SD of three independent experiments and show the leptin mRNA levels relative to those in 3T3-L1 cells in absence of BPA. Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. Asterisks indicate statistically significant differences (* p < 0.05). doi:10.1371/journal.pone.0082099.g004

Statistical analysis

Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. *p values of less than 0.05 were considered statistically significant.

Results

BPA down-regulates insulin-stimulated glucose utilization in differentiated adipocytes

We have first investigated whether BPA could affect glucose utilization in differentiated adipocytes. To this end, human adipocytes, obtained following differentiation of adipose tissue-derived stromal vascular fraction (SVF) cells, were incubated with BPA (1 nM or 100 nM), for 8, 24 and 48h, in the absence or in the presence of insulin (100 nM). Following BPA treatment, glucose utilization tended to be increased, at each time point (data not shown). As expected, in the absence of BPA, insulin induced a significant 4.5 fold increase of glucose utilization. Insulin stimulatory effect was still detectable after 8h incubation with 1 nM BPA, while after 24h of incubation with BPA, insulin effect on glucose utilization was reduced by 55% (Fig 1a). Within the same time frame, 100 nM BPA decreased insulin stimulatory action by >70%. Prolonging BPA pre-exposure to 48h, further reduced insulin effect. Consistent results were obtained following identical treatment of differentiated 3T3-L1 adipocytes (Fig 1b). Thus, 1 nM BPA treatment for 24h was sufficient to inhibit insulin effect on glucose utilization both in differentiated human adipocytes and in 3T3-L1 cells. Therefore, for the next experimental settings we have used 1 nM BPA, as the lowest non toxic dose.

No relevant morphological abnormalities were observed following BPA exposure (up to 48h) both for human and 3T3-L1 adipocytes.

Moreover, 1 nM BPA did not roughly affect adipocyte differentiation. Indeed, when 3T3-L1 pre-adipocytes were incubated with BPA along with the differentiation mix, during early (day 2), medium (day 6) and late (day 10) adipogenesis phases, PPARγ (Fig.2a) and GLUT4 (Fig.2b) mRNA levels were unchanged. At variance, GLUT1 levels were increased, following BPA exposure (Fig.2c). Consistent results were obtained with human pre-adipocytes (data not shown).

BPA inhibits insulin receptor phosphorylation and downstream signalling in differentiated adipocytes

We have therefore analyzed the effect of BPA on insulin signalling in mature adipocytes. Human (Fig. 3a-b) and 3T3-L1 (Fig.3c-d) adipocytes were pre-incubated with 1 nM BPA for 24h and 48h and then stimulated with insulin for 10 min. BPA exposure led to a time-dependent decrease of insulin-stimulated

Table 2. BPA interference on adipocyte-released cytokines.

|        | Human Adipo (pg/ml) | Human Adipo + BPA (pg/ml) | Adipo3T3-L1(pg/ml) | Adipo3T3-L1 +BPA (pg/ml) |
|--------|---------------------|---------------------------|-------------------|-------------------------|
| IL-1b  | ND                  | 60.58±9                   | 55.36±7.4         | ND                      |
| IL-2   | 9.63±1.2            | 9.68±0.8                  | ND                | ND                      |
| IL-4   | 8.23±0.9            | 8.55±0.9                  | 0.13±0.02         | 0.9±0.008               |
| IL-6   | 689.7±72.5          | 884.9±93.4*               | 0.98±0.03         | 5.27±0.7**              |
| IL-10  | 85.01±9.2           | 83.15±9.7                 | 3.70±0.4          | 4.39±0.8                |
| GM-CSF | 112.3±15.6          | 114.41±13.1               | ND                | ND                      |
| IFN-γ  | 393.79±42.6         | 481.71±45.7*              | 0.25±0.09         | 0.86±0.05*              |
| KC/IL-8| 56.81±6.9           | 63.63±6.1                 | 20566±215         | 21283±200.3             |
| MIP-1a | 2.44±0.9            | 2.52±0.7                  | 26.22±3.2         | 43.48±5.6*              |
| MIP-1b | 13.68±1.9           | 14.07±2                   | 2.35±0.52         | 1.26±0.3                |
| RANTES | 25.08±3.1           | 25.94±2.3                 | 362.75±39.2       | 333.3±27.9              |
| TNF-α  | 11.12±1.3           | 11.37±1                   | 255.91±27.1       | 222.07±21.9             |

Supematants from 3T3-L1 and human adipocytes treated with or without 1 nM BPA for 24h were collected and tested by using the Bioplex multiplex cytokine assay kit as described in Materials and Methods. Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically significant. Asterisks indicate statistically significant differences (* p<0.05; ** p<0.01).

doi:10.1371/journal.pone.0082099.t002
insulin receptor (IR) tyrosine phosphorylation and to a significant reduction of PKB/Akt and ERK1/2 phosphorylation. No significant BPA-dependent change was observed for IR, PKB/Akt and ERK1/2 total protein or basal phosphorylation levels.

BPA exposure affects adipocyte secretion and induces activation of inflammation-related pathways in adipocytes

We assessed whether BPA could affect the expression of specific adipokines. To this end, we have measured leptin mRNA levels in 3T3-L1 cells. A significant decrease in leptin mRNA levels was found following treatment with 1 nM BPA, compared the control cells (Fig.4).

We have next analyzed the impact of 1 nM BPA on adipocyte secretory function, in terms of release of inflammatory cytokines (Table 2). Both human and 3T3-L1 differentiated adipocytes displayed higher levels of IL-6 and IFN-γ. No significant difference was found for several other cytokines (IL-1β, IL-2, IL-4, IL-6, IL-10, GM-CSF, IFN-γ, KC/IL-8, MIP-1α, MIP-1β, RANTES and TNF-α) with the exception of MIP-1α, which was significantly elevated in BPA-treated 3T3-L1, while not in human adipocytes. Some other cytokines (IL-1α, IL-3, IL-5, IL-9, IL-12 p40, IL-12p70, IL-13, IL-17, Eotaxin, G-CSF, MCP-1) were not detected.

**Figure 5. Effect of BPA on JNK and STAT3 activation.** Human (a) and 3T3-L1 (c) adipocytes were incubated with 1 nM BPA for 24h and then solubilized as described in Materials and Methods. Cell lysates (50 μg protein/sample) were blotted with phospho-Thr183/Tyr185 JNK and Phospho-Tyr705 STAT3 antibodies and then reblotted with anti-JNK and STAT3 antibodies. To ensure the equal protein transfer, membranes were blotted with actin antibodies. The filters were revealed by ECL and autoradiography. The autoradiographs shown are representative of four independent experiments. b-d) Filters obtained in a and c have been analyzed by laser densitometry as described under Materials and Methods. Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically significant. Asterisks indicate statistically significant differences (*p<0.05). Error bars indicate mean ± S.D.
inhibition occurring after BPA treatment alone. Indeed, in the presence of SP600125 insulin on insulin signalling pathway, the compound reverted BPA and insulin-stimulated cells (Fig. 8). Consistent with the effect therefore tested the effect of SP600125 on glucose utilization on with SP600125 largely rescued insulin effect on IR, PKB/Akt and STAT3 phosphorylation, however. Interestingly, the treatment phosphorylation (Fig. 7a-b). We also observed a slight inhibition of this concentration the compound inhibited BPA-stimulated JNK decreased cytosolic abundance (Fig.6).

Next, human adipocytes were treated with 20 nM SP600125. At this concentration the compound inhibited BPA-stimulated JNK phosphorylation (Fig. 7a-b). We also observed a slight inhibition of STAT3 phosphorylation, however. Interestingly, the treatment with SP600125 largely rescued insulin effect on IR, PKB/Akt and ERK1/2 phosphorylation in BPA-stimulated cells (Fig.7c-d). We therefore tested the effect of SP600125 on glucose utilization on BPA-and insulin-stimulated cells (Fig. 8). Consistent with the effect on insulin signalling pathway, the compound reverted BPA inhibitory effect. Indeed, in the presence of SP600125 insulin action appeared inhibited by only 30%, compared to 55% inhibition occurring after BPA treatment alone.

**Discussion**

Many environmental pollutants, including BPA, are lipophilic compounds with small size and with the ability to mimic or block the natural action of endogenous hormones [26]. For this capability, they may affect several endogenous pathways, including those regulating energy and glucose metabolism, thereby contributing to insulin resistance and metabolic dysfunction [36].

Moreover, environmental pollutants, as well as excessive nutrients, can trigger inflammatory signals. There is a large body of evidence indicating that obesity is accompanied by inflammation in metabolically relevant tissues, particularly in adipose tissue [7–10,37]. It is therefore possible that pollutants may participate in deranging the function of adipose tissue, contributing to the inflammatory condition and to insulin resistance.

We have now provided evidence that nanomolar BPA concentrations may induce an inflammation-like response in human adipocytes. BPA exposure of human adipocytes increases the release of inflammatory factors, such as IL-6 and IFN-γ, raising the possibility that it may directly elicit a pseudo-inflammatory response in adipose tissue. Another consistent finding is the activation of typical inflammatory pathways. Indeed, JNK, JAK/STAT and NF-κB pathways have been found activated in BPA-treated adipocytes. Thus, both secretion of cytokines and activation of intracellular pathways, suggestive of an inflammatory response, occur after treatment with very low doses of BPA, comparable to those commonly found in the environment and in biological samples [28,29]. The direct stimulation of BPA on inflammatory pathways in adipocytes could also be accompanied, in vivo, by an effect on inflammatory infiltrates in the adipose tissue [8–10,38].

It has been hypothesized that BPA can trigger Toll-like Receptors (TLR), which in turn may induce JNK and NF-κB pathways, leading to up-regulation of pro-inflammatory factors, including IL-6 and IFN-γ [38,39]. Alternatively, BPA may act through estrogen receptors both at genomic and at non-genomic level [39,40]. Recent evidence also indicates that BPA specifically binds G protein-coupled receptor 30 (GPR30), a novel non-classical membrane ER, by which estrogenic compounds might induce biological effects in different cell types, including adipocytes [39,41,42].

Thus, one might speculate that BPA elicits intracellular signalling pathways (either via TLR, ER or GPR30) leading to up-regulation of IL-6 and IFN-γ, which in turn may contribute to activate typical inflammatory pathways, such as JNK and JAK/STAT. Consistent with our findings, other groups have shown that IL-6 release is increased following BPA exposure of human pre-adipocytes [39,43]. To the best of our knowledge, this is the first report of IFN-γ release elicited by BPA in adipocytes, while it has been described in dendritic cells and in CD4+ lymphocytes [39,43].

In parallel with the pseudo-inflammatory profile, we observed that BPA-treated adipocytes were less sensitive to insulin in terms of glucose utilization. Interestingly, the effect was already detectable upon treatment of the cells with 1 nM BPA. At this concentration, we failed to observe any gross abnormality in adipocyte morphology and differentiation markers, including GLUT4, suggesting that the alteration specifically occurred at the level of the insulin signalling machinery. Other laboratories have reported that BPA stimulated an increase in GLUT4 and glucose uptake in adipocytic cell models [44]. However, these in vitro effects required doses considerably higher than those found in human tissues [28]. Nonetheless, we observed increased basal glucose utilization, accompanied by increased levels of GLUT1. The possibility of reduced total glucose uptake is, therefore, not supported by data. At variance, we observed reduced insulin-stimulated tyrosine phosphorylation of insulin receptor and a consistent reduction of downstream signalling. In agreement with Kidani et al [45], these alterations can be responsible for a worsening in insulin signalling via PKB/Akt and ERK, causing a reduction in insulin sensitivity and in insulin-mediated glucose uptake in adipose tissue. This also raises the possibility that BPA-induced insulin sensitivity may contribute to worsen the pro-inflammatory profile. Indeed, an emerging body of evidence suggests that insulin suppresses the inflammatory process, not only through preventing hyperglycemia but also by modulating the conditioned media of either human and 3T3-L1 differentiated adipocytes.

This led us to hypothesize that BPA may elicit an inflammatory-like response in adipocytes. We also observed a significantly increased detection of the phosphorylated forms of JNK and STAT3 in human (Fig. 5a-b) and 3T3-L1 (Fig. 5c-d) adipocytes upon treatment with BPA for 24h.

Consistently, 1 nM BPA treatment led to a significantly increased detection of NF-κB in nuclear extracts, paralleled by a decreased cytosolic abundance (Fig.6).

**Figure 6. Effect of BPA on NFkB activation.** 3T3-L1 adipocytes were incubated with 1 nM BPA for 24h. Next, subcellular fractionation(-nuclear and cytoplasmic) was performed and proteins were extracted and subjected to SDS-PAGE and immunoblotted with anti-NFkB antibody. Actin and Laminin A/C were used as loading control for the cytosolic and nuclear fractions, respectively. Blots were revealed by ECL and autoradiography. The autoradiographs shown are representative of four independent experiments.

doi:10.1371/journal.pone.0082099.g006
Moreover, the decrease of leptin levels observed in BPA-treated adipocytes may be due to reduced insulin promotion of leptin gene expression, as previously reported in human adipocytes [47,48].

Interestingly, however, inhibition of JNK activity almost completely restored insulin receptor signalling and largely rescued insulin-stimulated glucose utilization in BPA-treated adipocytes, suggesting a primary involvement of inflammatory factors.

Although no gross effect on adipocyte morphology and differentiation was observed, we cannot exclude the possibility that pre-natal or early post-natal exposure to BPA may affect adipogenesis as well, as has also been reported [49–53].

**Figure 7. Effect of JAK2/STAT3 and JNK inhibition on BPA-impaired inflammatory and insulin pathways.** Human adipocytes were incubated with 1 nM BPA for 24h and exposed to 20 μM SP600125 for 1 h. a) Cell lysates (50 μg protein/sample) were blotted with phospho-JNK and Phospho-Tyr705 STAT3 antibodies and then rebotted with anti-JNK and STAT3 antibodies. c) Cells were treated with 100 nM insulin for 10 min and then solubilized. Cell lysates (50 μg protein/sample) were blotted with phospho-IR, phospho- Ser473 Akt/PKB and phospho-Thr202/ERK and then rebotted with anti-IR, Akt/PKB and ERK antibodies. To ensure the equal protein transfer, membranes were blotted with actin antibodies. The filters were revealed by ECL and autoradiography. The autoradiographs shown are representative of four independent experiments. b-d) Filters obtained in a and c have been analyzed by laser densitometry as described under Materials and Methods. Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically significant. Asterisks indicate statistically significant differences (* p<0.05). Error bars indicate mean± S.D.

doi:10.1371/journal.pone.0082099.g007
Thus, exposure to BPA impairs insulin sensitivity and induces the release of inflammatory factors in adipocytes. One possible mechanism is that BPA activates JNK, via TLRs or ERs, and this may directly impair insulin action [39,54]. Alternatively, the release of IL-6 and INF-γ may, in turn, contribute to JNK activation in the adipocytes and either directly or indirectly down-regulate insulin-stimulated glucose uptake [34].

It should be also pointed out that an associations between serum and urinary concentrations of persistent organic pollutants and diabetes have been described [13,33,56]. Moreover, we have recently reported that women with Polycystic Ovary Syndrome (PCOS), characterized by insulin resistance and low-grade chronic inflammation, displayed elevated serum BPA levels [57]. These observations indicate a relevant role for BPA in impairing energy and nutrient metabolism, and, together with our current report, suggest that adipocytes may integrate BPA signals and further derange insulin sensitivity and inflammatory pathways.

Acknowledgments

The authors are grateful to Dr. D. Ligozto for technical help and to Dr. C. Miele for helpful discussion and advise.

Author Contributions

Conceived and designed the experiments: RV PF FB FO. Performed the experiments: RVDE FP AL SC ML. Analyzed the data: RV VDE GP A. Contributed reagents/materials/analysis tools: SC FO. Wrote the paper: RV VDE PF.

References

1. Hossain P, Kaur B, El Nahas M (2007) Obesity and diabetes in the developing world—a growing challenge. N Engl J Med 356: 213–15.
2. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM (2010)Prevalence of high body mass index US children and adolescents, 2007–2008. JAMA 303: 242–49.
3. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB (2005) Metabolic syndrome as a predictor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112: 3066–3072.
4. Ritchie SA, Connell JM (2007) The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiov Dis 17: 319–326.
5. Hursting SD, Dunlap SM (2012) Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann N Y Acad Sci 1271: 82–7.
6. D’Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Terracciano D, et al. (2012) Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia 55(10): 2811–2822.
7. Hummassi S, Hotamisligil GS (2010) Endoplasmic Reticulum Stress and Inflammation in Obesity and Diabetes. Circ Res 107(5): 579–591.
8. Shapiro H, Lutaty A, Ariel A (2011) Macrophages, Meta-inflammation, and immuno-metabolism. Scientific World Journal 11: 2509–2529.
9. Gregor MF, Hotamisligil GS (2011) Inflammatory Mechanisms in Obesity. Ann Rev Immunol 29: 415–445.
10. Osborn O, Olufsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18: 363–374.
11. Newbold RR, Padilla-Banks E, Jefferson WN (2005) Developmental exposure to bisphenol A (BPA). Reprod Toxicol 24: 139–177.
12. Rubin BS, Soto AM (2009) Bisphenol A: perinatal exposure and body weight. Mol Cell Endocrinol 304: 55–62.
13. Vandenberg LN, Hauser R, Marcus M, Olea N, Wdbrohn WV (2007) Human exposure to bisphenol A (BPA). Reprod Toxicol 24: 139–177.
14. Szyman´ski A, Rykowska I, Wasiak W (2006) Determination of bisphenol-a in environmental samples by liquid chromatography–mass spectrometry. Acta Chromatograph 17: 407–34.
15. Somm E, Schwizgebel VM, Toulotte A, Cederroth CR, Combescure C, et al. (2009) Perinatal exposure to bisphenol A alters early adipogenesis in the rat. Environ Health Perspect 117: 1549–1555.
16. Carwile JL, Michels KB (2011) Urinary bisphenol a and obesity: NHANES 2003–2006. Environ Res 111: 825–830.
17. Rubin BS (2011) Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol 127: 27–34.
18. Everett CJ, Friithsen I, Player M (2011) Relationship of polychlorinated biphenyls with type 2 diabetes and hypertension. J Environ Monit 13: 241–51.
19. Carpenter DO (2008) Environmental contaminants as risk factors for developing diabetes. Rev Environ Health 23: 59–74.
20. Grun F, Blumberg B (2007) Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev Endocr Metabol Disord 8: 161–171.
21. Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN (2005) Developmental Exposure to Estrogic Compounds and Obesity. Birth Defects Res A Clin Mol Teratol. (Part A) 73: 478–480.
viral infectivity via ERK-mediated signals in glioma cells. Hum Gene Ther. 21: 1067–76.
36. vom Saal FS, Hughes C (2005). An extensive new literature concerning low-dose effects of bisphenol-A shows the need for a new risk assessment. Environ Health Perspect 113: 926–933.
37. Isakson P, Hammarstedt A, Gustafson B, Smith U (2009) Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes 58: 1550–1557.
38. Calippe B, Douin-Echinard V, Delpy L, Laffargue M, Lèupil K, et al. (2010) 17β-estradiol promotes TLR4-triggered proinflammatory mediator production through direct estrogen receptor alpha signaling in macrophages in vivo. J Immunol 185: 1169–1176.
39. Rogers JA, Metz L, Yong VW (2013) Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. Mol Immunol 53: 421–430.
40. Bernal AJ, Jirtle RL (2010) Epigenomic disruption: the effects of early developmental exposures. Birth Defects Res A Clin Mol Teratol 88: 938–944.
41. Ben-Jonathan N, Hugo ER, Brandebourg TD (2009) Effects of bisphenol A on adipokine release from human adipose tissue: Implications for the metabolic syndrome. Mol Cell Endocrinol 304: 49–54.
42. Wadia PR, Cabaton NJ, Borrello MD, Rubin BS, Sonnenschein C, et al. (2013) Low-dose BPA exposure alters the mesenchymal and epithelial transcriptomes of the mouse fetal mammary gland. PLoS One 8: e63902.
43. Siracusa MC, Overstreet MG, Housseau F, Scott AL, Klein SL (2008) 17β-estradiol alters the activity of conventional and IFN-producing killer dendritic cells. J Immunol 180: 1423–1431.
44. Sakurai K, Kawazuma M, Adachi T, Harigaya T, Saito Y, et al. (2004) Bisphenol A affects glucose transport in mouse 3T3-F442A adipocytes. Br J Pharmacol 141: 209–214.
45. Kidani T, Kamei S, Miyawaki J, Azawaj A, Sakayama K, et al. (2010) Bisphenol A downregulates Akt signaling and inhibits adiponectin production and secretion in 3T3-L1 adipocytes. J Atheroscler Thromb 17: 834–843.
46. Hyun E, Ramachandran R, Holleinberg MD, Vergnaud N (2011) Mechanisms behind the anti-inflammatory actions of insulin. Crit Rev Immunol 31: 307–40.
47. Wabitsch M, Jensen PB, Blum WF, Christoffersen CT, Englaro P, et al. (1996) Insulin and cortisone promote leptin production in cultured human fat cells. Diabetes. 45: 1435–8.
48. Russell CS, Petersen RN, Rao SP, Ricci MR, Prasad A, et al. (1998) Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. Am J Physiol 273: E507–E513.
49. Sargis RM, Johnson DN, Choudhury RA, Brady MJ (2010) Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorticoid receptor activation. Obesity (Silver Spring)18: 1283–1288.
50. Golub MS, Wu KL, Kaufman FL, Li LH, Moran-Messen F, et al. (2010) Bisphenol A: developmental toxicity from early prenatal exposure. Birth Defects Res B Dev Reprod Toxicol. 89: 441–466.
51. Wei J, Lin Y, Li Y, Ying C, Chen J, et al. (2011) Perinatal exposure to bisphenol A at reference dose predisposes offspring to metabolic syndrome in adult rats on a high-fat diet. Endocrinology 152: 3049–3061.
52. Ryan KK, Haller AM, Sorrell JE, Woods SC, Jandacek RJ, et al. (2010) Ryan KK, Haller AM, Sorrell JE, Woods SC, Jandacek RJ, et al. (2010) Perinatal exposure to bisphenol-a and the development of metabolic syndrome in CD-1 mice. Endocrinology 151: 2603–2612.
53. Miao M, Yuan W, Zhu G, He X, Li DK (2011) In utero exposure to bisphenol-A and its effect on birth weight of offspring. Reprod Toxicol 32: 64–68.
54. Tilg H, Moschen AR (2008) Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14: 222–31.
55. Shankar A, Teppala S (2011) Relationship between urinary bisphenol A levels and diabetes mellitus. J Clin Endocrinol Metab 96: 3822–6.
56. Silver MK, O’Neill MS, Sowers MR, Park SK (2011) Urinary bisphenol A and type-2 diabetes in U.S. adults: data from NHANES 2003–2008. PLoS One 6: e26068.
57. Tarantino G, Valentino R, Di Somma C, Orso F, Piovella G, et al. (2012) Bisphenol-A in Polycystic Ovary Syndrome and its association with liver-spleen axis. Clin. Endocrinol (Oxf.) 78: 447–453.